Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EVH
EVH logo

EVH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Evolent Health Inc (EVH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.950
1 Day change
1.28%
52 Week Range
12.060
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

EVH is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 available, especially since the user is unwilling to wait for a better entry. The stock is showing a weak technical setup, there is no fresh news catalyst, and financial data is unavailable to confirm fundamental improvement. While analyst targets were recently raised and the stock may have upside versus the current price, the current evidence is not strong enough to make it an immediate buy.

Technical Analysis

EVH is in a bearish technical structure. The MACD histogram is negative at -0.0658 and still contracting, RSI_6 is neutral at 52.322, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 3.90 is below the pivot of 3.977 and below resistance levels R1 at 4.242 and R2 at 4.406, while support sits at 3.711 and 3.547. This suggests the stock is still under pressure and lacks a clear bullish breakout trend. The short-term pattern estimate shows only modest upside probabilities, not a strong trend reversal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish. The open interest put-call ratio of 0.7 shows more calls than puts on positioning, and the option volume put-call ratio of 0.09 is strongly call-skewed for the day, suggesting traders are leaning bullish. However, total volume is low at 100, and the stock's high IV level means options are priced for elevated movement. Overall, options sentiment is positive but not strong enough to override the weak chart.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
5

Positive Catalysts

  • ["Citi raised EVH's price target to $5.50 from $4 and maintained a Buy rating.", "Canaccord raised its price target to $6 from $5 and kept a Buy rating.", "Analysts noted the company continues to win new business despite mixed Q1 results.", "Options flow is somewhat bullish based on a low put-call volume ratio."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "Technical trend remains bearish with moving averages stacked negatively.", "MACD remains below zero and weakening.", "Hedge funds and insiders are both neutral with no meaningful buying trend.", "No recent congress trading data was available.", "Financial snapshot data is unavailable, so recent quarter fundamental momentum cannot be confirmed."]

Financial Performance

Latest quarter financials were not provided due to an error, so there is no usable quarterly revenue or earnings snapshot to evaluate. Because the latest quarter season is unavailable, I cannot confirm growth acceleration or margin improvement from the supplied data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend is positive: Citi increased its target to $5.50 from $4 and Canaccord raised its target to $6 from $5, with both firms maintaining Buy ratings. This shows Wall Street pros are constructive on the name and see upside from the current $3.90 price. The bull case is that EVH may recover toward higher targets if execution improves. The bear case is that the current price action and lack of fresh catalysts do not yet confirm that recovery.

Wall Street analysts forecast EVH stock price to rise
14 Analyst Rating
Wall Street analysts forecast EVH stock price to rise
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.900
sliders
Low
5
Averages
9.33
High
16
Current: 3.900
sliders
Low
5
Averages
9.33
High
16
Citi
Buy
maintain
$4
AI Analysis
2026-05-15
Reason
Citi
Price Target
$4
AI Analysis
2026-05-15
maintain
Buy
Reason
Citi raised the firm's price target on Evolent Health to $5.50 from $4 and keeps a Buy rating on the shares.
Canaccord
Buy
maintain
$5 -> $6
2026-05-12
Reason
Canaccord
Price Target
$5 -> $6
2026-05-12
maintain
Buy
Reason
Canaccord raised the firm's price target on Evolent Health to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model following mixed Q1 results and where the company showed they continue to win new business.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EVH
Unlock Now

People Also Watch